免疫腫瘍薬市場：治療タイプ別、疾患タイプ別、流通チャネル別、地域別

世界の免疫腫瘍薬市場は、2024年に272億5,000万米ドルと推定され、2024年から2031年までのCAGRは18.4％を示し、2031年には891億米ドルに達すると予測されます。

図.免疫腫瘍薬市場シェア（%）、2024年地域別

免疫腫瘍薬は、身体の免疫システムを利用してがんと闘うもので、さまざまながん種で生存率の向上が実証されています。これらの薬剤はがん細胞に対する免疫反応を高め、生存率を向上させる。承認されている主な免疫腫瘍薬クラス別には、チェックポイント阻害剤、がんワクチン、非特異的免疫療法などがあります。有効性と安全性を改善した新規薬剤の継続的な臨床研究と開発が、市場成長の原動力となっています。

市場力学：

世界の免疫腫瘍薬市場の成長は、主に世界のがん罹患率の上昇によってもたらされます。がん罹患率は、ライフスタイルの変化、平均寿命の伸び、公害などの環境要因のために年々上昇しています。免疫腫瘍治療薬は、従来のがん治療薬と比較して長期的な有効性と生存率が高いことが実証されています。このことは、医薬品の研究開発を後押しし、医薬品の承認を増加させています。コンパニオン診断の発展により、免疫療法に最も適した患者集団が特定されるため、市場の成長が促進されます。しかし、これらの薬剤は高価であるため、価格に敏感な地域では採用が制限される可能性があります。また、免疫関連の副作用などの安全性の問題も市場成長の妨げとなる可能性があります。新たな適応症、薬剤の組み合わせ、個別化療法を評価する臨床試験が進行中であるため、近い将来、市場成長に有利な機会がもたらされる可能性があります。

本調査の主な特徴

• 本レポートでは、世界の免疫腫瘍薬市場を詳細に分析し、2023年を基準年とした予測期間（2024-2031年）の市場規模（10億米ドル）と年間平均成長率（CAGR%）を掲載しています。
• また、さまざまなセグメントにわたる潜在的な収益機会を明らかにし、この市場の魅力的な投資提案マトリクスについて解説しています。
• また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。
• 企業ハイライト、製品ポートフォリオ、主要なハイライト、財務実績、戦略などのパラメータに基づいて、世界の免疫腫瘍薬市場の主要企業をプロファイルしています。
• 本レポートからの洞察は、マーケティング担当者や企業の経営陣が、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことを可能にするでしょう。
• 免疫腫瘍薬の世界市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界の様々な利害関係者を対象としています。
• 利害関係者は、世界の免疫腫瘍薬市場の分析に使用される様々な戦略マトリックスを通じて、意思決定が容易になります。

目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場の展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー
• Coherent Opportunity Map（COM）

第3章 市場力学、規制、動向分析

• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• 影響分析
• 市場動向
• 主な発展
• 規制シナリオ
• 買収と提携のシナリオ
• 資金調達と投資
• PEST分析
• ポーターの分析

第4章 世界の免疫腫瘍薬市場- コロナウイルス（COVID-19）パンデミックの影響

• 全体的な影響
• 政府の取り組み
• COVID-19による市場への影響

第5章 世界の免疫腫瘍薬市場、治療タイプ別、2019年-2031年

• 免疫チェックポイント阻害剤
• PD-1
• PD-LI
• CTLA-4
• 免疫システム調節剤
• がんワクチン
• 腫瘍溶解性ウイルス
• その他

第6章 世界の免疫腫瘍薬市場、疾患タイプ別、2019年-2031年

• 悪性黒色腫
• 肺がん
• 血液がん
• 腎細胞がん
• 前立腺がん
• 膀胱がん
• その他

第7章 世界の免疫腫瘍薬市場、流通チャネル別、2019年-2031年

• 病院薬局
• 小売薬局
• オンライン薬局

第8章 世界の免疫腫瘍薬市場、地域別、2019年-2031年

• ラテンアメリカ
• 欧州
• アジア太平洋
• 中東

第9章 競合情勢

• 企業プロファイル
  • Coloplast Corp
  • Bristol Myers Squibb Company
  • Novartis AG
  • F. Hoffmann-LA Roche Ltd.
  • Merck &Co., Inc.
  • GSK Plc.
  • Eli Lilly and Company
  • Fresenius Kabi AG
  • Pfizer Inc.
  • AbbVie Inc.
  • Genentech Inc.
  • Sanofi
  • AstraZeneca
  • Bayer AG
  • Bluebird Bio, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Amgen Inc.

第10章 アナリストの推奨事項

• 運命の輪
• アナリストの見解
• 一貫した機会マップ

第11章 参考文献と調査手法

• 参考文献
• 調査手法

Global immuno-oncology drugs market is estimated to be valued at USD 27.25 Bn in 2024 and is expected to reach USD 89.10 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 18.4% from 2024 to 2031.

Figure. Immuno-oncology Drugs Market Share (%), By Region 2024

Immuno-oncology drugs use the body's immune system to fight cancer, and have demonstrated improved survival rates for various cancer types. These drugs boost the immune response against cancer cells, and thus, improve survival outcomes. Some major immuno-oncology drug classes approved include checkpoint inhibitors, cancer vaccines, and nonspecific immunotherapies. Continued clinical research and development of novel agents with improved efficacy and safety profiles can drive the market growth.

Market Dynamics:

Global immuno-oncology drugs market growth is primarily driven by rising cases of cancer worldwide. Cancer incidence has been rising year-on-year owing to lifestyle changes, increased life expectancy, and environmental factors like pollution. Immuno-oncology drugs have demonstrated long-term efficacy and survival benefits as compared to conventional cancer therapies. This boosts pharmaceutical R&D and increases drug approvals. The developments in companion diagnostics identify patient populations most suitable for immunotherapies, thus, driving the market growth. However, high costs of these drugs can restrict its adoption in price-sensitive regions. Safety issues like immune-related adverse effects can also hamper the market growth. Ongoing clinical trials evaluating new indications, drug combinations, and personalized therapies can offer lucrative opportunities for the market growth in the near future.

Key Features of the Study:

• This report provides in-depth analysis of the global immuno-oncology drugs market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global immuno-oncology drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Bristol-Myers Squibb, Merck, Roche, Pfizer, AstraZeneca, and Novartis
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global immuno-oncology drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global immuno-oncology drugs market

Detailed Segmentation-

• By Treatment Type
  • Immune Checkpoint Inhibitors
  • PD-1
  • PD-LI
  • CTLA-4
  • Immune System Modulators
  • Cancer Vaccines
  • Oncolytic Virus
  • Others
• By Disease Type
  • Melanoma
  • Lung Cancer
  • Blood Cancer
  • Renal Cell Carcinoma
  • Prostate Cancer
  • Bladder Cancer
  • Others (Breast Cancer, Thyroid Cancer, etc.)
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Coloplast Corp
  • Bristol Myers Squibb Company
  • Novartis AG
  • F. Hoffmann-LA Roche Ltd.
  • Merck & Co., Inc.
  • GSK Plc.
  • Eli Lilly and Company
  • Fresenius Kabi AG
  • Pfizer Inc.
  • AbbVie Inc.
  • Genentech Inc.
  • Sanofi
  • AstraZeneca
  • Bayer AG
  • Bluebird Bio, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Amgen Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Treatment Type
  • Market Snapshot, By Disease Type
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Immuno-oncology Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Immuno-oncology Drugs Market, By Treatment Type, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Immune Checkpoint Inhibitors
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• PD-1
• PD-LI
• CTLA-4
• Immune System Modulators
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Cancer Vaccines
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Oncolytic Virus
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Immuno-oncology Drugs Market, By Disease Type, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Melanoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Lung Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Blood Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Renal Cell Carcinoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Prostate Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Bladder Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Immuno-oncology Drugs Market, By Distribution Channel, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Immuno-oncology Drugs Market, By Region, 2019 - 2031, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2031
  • Regional Trends
    • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2019 - 2031, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profiles
  • Coloplast Corp
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Bristol Myers Squibb Company
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • F. Hoffmann-LA Roche Ltd.
  • Merck & Co., Inc.
  • GSK Plc.
  • Eli Lilly and Company
  • Fresenius Kabi AG
  • Pfizer Inc.
  • AbbVie Inc.
  • Genentech Inc.
  • Sanofi
  • AstraZeneca
  • Bayer AG
  • Bluebird Bio, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Amgen Inc.

10. Analyst Recommendation

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About Us and Sales Contact